Lipid regulators, also known as lipid-lowering drugs or hypolipidemic agents, are medications used to control blood lipid levels, specifically cholesterol and triglycerides. The main role of lipid regulators is to minimize the risk of cardiovascular disease, while they also contain anti-inflammatory properties that can help stabilize existing plaques and reduce the possibility of plaque rupture and related cardiovascular events.
Sizing and Forecast
The lipid regulators market size has grown strongly in recent years. It will grow from $6.83 billion in 2023 to $7.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to the increased prevalence of lifestyle diseases, growth in aging population, increased awareness of lipid regulators, increased healthcare expenditure, increased focus on healthcare prevention.
The lipid regulators market size is expected to see strong growth in the next few years. It will grow to $9.55 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, rising incidence of atherosclerosis with aging, increasing obesity rates, the rising prevalence of metabolic syndrome, growing focus on personalized medicine. Major trends in the forecast period include advancements in drug development, integration of digital health solutions, adoption of value-based pricing models, increase demand for over-the-counter, enhancing patient-cantered medication.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/lipid-regulators-global-market-report
Segmentation & Regional Insights
The lipid regulators market covered in this report is segmented –
1) By Type: Lipid Regulators, Narcotic Analgesics, Angiotensin Converting Enzyme (ACE) Inhibitors, Respiratory Agents, Diuretics, Calcium Antagonists, Hormonal Contraceptives, Other Types
2) By Indication: Hypercholesterolemia, Hypertriglyceridemia, Coronary Artery Disease, Other Indications
3) By Administration: Oral, Injectable
4) By Application: Pharmaceuticals, Vaccines And Drugs, Scientific Research, Nutrition And Supplements, Food And Beverages, Other Applications
North America was the largest region in the lipid regulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid regulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15848&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of ischemic heart disease is expected to propel the growth of the lipid regulator market going forward. Ischemic heart disease (IHD), commonly known as coronary artery disease (CAD), is a disorder in which the coronary arteries restrict or become blocked, resulting in reduced blood flow to the heart muscle. Ischemic heart disease (IHD) is increasing due to factors such as unhealthy diets, smoking, obesity, hypertension, and diabetes. Lipid regulators help in ischemic heart disease by lowering LDL cholesterol, raising HDL cholesterol, stabilizing arterial plaques, reducing inflammation, and improving endothelial function, thereby reducing the risk and severity of ischemic events. For instance, in December 2023, according to the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency for public health and welfare, between 2020 and 2021, there were 160,000 hospitalizations due to ischemic heart disease (IHD). In 2021, ischemic heart disease (IHD) caused 17,300 deaths. Therefore, the increasing prevalence of ischemic heart disease (IHD) is driving the growth of the lipid regulator market.
Key Industry Players
Major companies operating in the lipid regulators market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Limited, Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Alnylam Pharmaceuticals Inc., Amarin Corporation plc, Arrowhead Pharmaceuticals Inc., Kowa Pharmaceuticals America Inc. , Esperion Therapeutics Inc., Bentley Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Andrx Corporation
The lipid regulators market report table of contents includes:
1. Executive Summary
- Lipid Regulators Market Characteristics
- Lipid Regulators Market Trends And Strategies
- Lipid Regulators Market – Macro Economic Scenario
- Global Lipid Regulators Market Size and Growth
.
32. Global Lipid Regulators Market Competitive Benchmarking
- Global Lipid Regulators Market Competitive Dashboard
- Key Mergers And Acquisitions In The Lipid Regulators Market
- Lipid Regulators Market Future Outlook and Potential Analysis
- Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
